Company intelligence / Profile preview

Hybritech

San Diego, California, United States

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

Hybritech pioneered the use of monoclonal antibodies in diagnostics and developed the first commercial PSA test, regarded as the most accurate method for monitoring prostate cancer in its era. Several other diagnostic kits for anemia, various cancers, and allergies reached the market before its acquisition.

Therapeutic areas: HematologyOncologyInfectious DiseasesImmunology
Modalities: Monoclonal antibody
Industry: Protein Biomarker Diagnostics

Partnerships

Kleiner Perkins Caufield & Byers (early investor)

Beyond the preview

Go deeper on Hybritech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hybritech.

Explore the full profile